{"id":730258,"date":"2025-02-05T07:30:01","date_gmt":"2025-02-05T07:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=730258"},"modified":"2025-02-05T07:30:01","modified_gmt":"2025-02-05T07:30:01","slug":"lipodystrophy-market-expected-to-rise-2034-ionis-pharmaceuticals-regeneron-pharmaceuticals-boehringer-ingelheim-expected-to-drive-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lipodystrophy-market-expected-to-rise-2034-ionis-pharmaceuticals-regeneron-pharmaceuticals-boehringer-ingelheim-expected-to-drive-market_730258.html","title":{"rendered":"Lipodystrophy Market Expected to rise, 2034 | Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, expected to drive market"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/02\/1738683836.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Lipodystrophy Market Expected to rise, 2034 | Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, expected to drive market\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/02\/1738683836.jpg\" alt=\"Lipodystrophy Market Expected to rise, 2034 | Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, expected to drive market\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Lipodystrophy Market 2034<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Lipodystrophy market growth is driven by factors like increase in the prevalence of Lipodystrophy, investments in research and development, entry of emerging therapies during the study period 2020-2034.<\/div>\n<p style=\"text-align: justify;\">The <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-market?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Lipodystrophy market report<\/a> also offers comprehensive insights into the Lipodystrophy market size, share, Lipodystrophy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Lipodystrophy market size growth forward.<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key highlights from the Lipodystrophy Market Insights Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Several key pharmaceutical companies, including Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others, are developing novel products to improve the Lipodystrophy treatment outlook.<\/p>\n<\/li>\n<li>\n<p>In November 2024, Amryt Pharma initiated an open-label extension of the APG-20 study to assess the long-term safety and efficacy of daily subcutaneous metreleptin treatment in individuals with partial lipodystrophy. This Phase 3 study aims to continue evaluating metreleptin&#8217;s long-term impact on this patient population.<\/p>\n<\/li>\n<li>\n<p>Lipodystrophy is a rare condition characterized by abnormal fat distribution in the body, which can lead to either fat loss (lipoatrophy) or fat accumulation in unusual areas (lipohypertrophy). According to DelveInsight&#8217;s 2023 estimates, there were around 3,077 prevalent cases of lipodystrophy across the 7MM, with the United States accounting for 35% of these cases.<\/p>\n<\/li>\n<li>\n<p>In 2023, 93% of diagnosed lipodystrophy cases were partial lipodystrophy, which predominantly affects females. This is primarily due to familial partial lipodystrophy (FPL), a common type linked to genetic mutations in the LMNA or PPARG genes, which are more frequent in women. Additionally, around 30% of lipodystrophy cases in the United States were classified as congenital generalized lipodystrophy, a condition marked by near-total fat loss, resulting in visible muscle mass, severe insulin resistance, early-onset diabetes, hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD).<\/p>\n<\/li>\n<li>\n<p>The US FDA has approved two therapies for lipodystrophy: MYALEPT (metreleptin) and EGRIFTA\/EGRIFTA SV (tesamorelin), produced by Amryt Pharma and Thera Technologies, respectively. The pipeline for lipodystrophy treatment is limited, with only a few companies advancing their candidates through clinical trials. Notable candidates include REGN4461 by Regeneron Pharmaceuticals, which is currently in Phase II. The rarity of the condition poses challenges for patient recruitment in clinical trials, slowing the development of new treatments.<\/p>\n<\/li>\n<li>\n<p>The US holds the largest share of the lipodystrophy market, driven by the high prevalence of the condition and the availability of approved treatments. MYALEPT (metreleptin) by Amryt Pharma plays a significant role, with its leptin-based therapy generating substantial revenue.<\/p>\n<\/li>\n<li>\n<p>As per DelveInsight analysis, the Lipodystrophy market is anticipated to witness growth at a considerable CAGR<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Strategise your business goals by understanding market dynamics @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-market?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Lipodystrophy Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Overview <\/strong><\/p>\n<p style=\"text-align: justify;\">Lipodystrophy is a rare condition characterized by abnormal fat distribution, either through fat loss (lipoatrophy) or fat buildup (lipohypertrophy). It can either be congenital (inherited) or develop later in life. This disorder often results in significant metabolic issues. Congenital forms include congenital generalized lipodystrophy (CGL), which causes extensive fat loss and metabolic problems like insulin resistance, and familial partial lipodystrophy (FPL), where fat is lost in certain areas and accumulates in others. Acquired lipodystrophy may develop later in life, sometimes linked to autoimmune diseases. Acquired generalized lipodystrophy (AGL) causes widespread fat loss, while acquired partial lipodystrophy (APL) leads to progressive fat loss in the upper body with accumulation in the lower body. HIV-associated lipodystrophy can occur as a side effect of antiretroviral treatment.<\/p>\n<p style=\"text-align: justify;\">Symptoms of lipodystrophy include fat loss in areas like the face, arms, legs, and buttocks, abnormal fat buildup in the neck and trunk, and metabolic problems such as insulin resistance and diabetes.<\/p>\n<p style=\"text-align: justify;\">Diagnosis typically involves a clinical assessment, metabolic tests, imaging techniques such as MRI or CT scans, and, in some cases, genetic testing or fat biopsies.<\/p>\n<p style=\"text-align: justify;\"><strong>Do you know the treatment paradigms for different countries? Download our <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-market?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Lipodystrophy Market Sample Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DelveInsight&#8217;s 2023 estimates suggest that there were around 3,077 prevalent cases of the rare disease lipodystrophy across the 7MM, with the United States representing 35% of these cases.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Epidemiology Segmentation <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s Lipodystrophy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Lipodystrophy historical patient pools and forecasted Lipodystrophy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Lipodystrophy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Lipodystrophy Prevalence<\/p>\n<\/li>\n<li>\n<p>Age-Specific Lipodystrophy Prevalence<\/p>\n<\/li>\n<li>\n<p>Gender-Specific Lipodystrophy Prevalence<\/p>\n<\/li>\n<li>\n<p>Diagnosed and Treatable Cases of Lipodystrophy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Visit for more @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-market?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Lipodystrophy Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Market Insights:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The US holds the largest share of the lipodystrophy market, due to the high prevalence of the condition and the presence of approved treatments. MYALEPT (metreleptin) by Amryt Pharma is a major contributor, with its leptin-based therapy generating significant revenue, around $880,000.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">The lipodystrophy treatment market is progressing, highlighting both existing and new therapies. In the United States, leading approved treatments such as MYALEPT (metreleptin) and EGRIFTA\/EGRIFTA SV (tesamorelin) dominate the market, generating significant revenue.<\/p>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Marketed Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>MYALEPT (metreleptin): Amryt Pharma<\/p>\n<\/li>\n<li>\n<p>EGRIFTA\/EGRIFTA SV (tesamorelin): Thera Technologies<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>REGN4461: Regeneron Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Subcutaneous Metreleptin: Amryt Pharma<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>For more information, visit <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-market?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Lipodystrophy Market Analysis, Patient Pool, and Emerging Therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Lipodystrophy Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>11 Years Forecast<\/p>\n<\/li>\n<li>\n<p>7MM Coverage<\/p>\n<\/li>\n<li>\n<p>Descriptive overview of Lipodystrophy, causes, signs and symptoms, diagnosis, treatment<\/p>\n<\/li>\n<li>\n<p>Comprehensive insight into Lipodystrophy epidemiology in the 7MM<\/p>\n<\/li>\n<li>\n<p>Lipodystrophy marketed and emerging therapies<\/p>\n<\/li>\n<li>\n<p>Lipodystrophy companies<\/p>\n<\/li>\n<li>\n<p>Lipodystrophy market drivers and barriers<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1 Lipodystrophy Market Key Comprehensive Insights<\/p>\n<p style=\"text-align: justify;\">2 Lipodystrophy Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">3 Competitive Intelligence Analysis for Lipodystrophy<\/p>\n<p style=\"text-align: justify;\">4 Lipodystrophy Market Analysis Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5 Executive Summary of Lipodystrophy<\/p>\n<p style=\"text-align: justify;\">6 Lipodystrophy Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">7 Lipodystrophy Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8 Lipodystrophy Patient Journey<\/p>\n<p style=\"text-align: justify;\">9 Lipodystrophy Treatment Algorithm, Lipodystrophy Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10 Key Endpoints in Lipodystrophy Clinical Trials<\/p>\n<p style=\"text-align: justify;\">11 Lipodystrophy Marketed Therapies<\/p>\n<p style=\"text-align: justify;\">12 Lipodystrophy Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13 Lipodystrophy: 7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14 Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15 Access and Reimbursement Overview of Lipodystrophy<\/p>\n<p style=\"text-align: justify;\">16 Lipodystrophy Market Key Opinion Leaders Reviews<\/p>\n<p style=\"text-align: justify;\">18 Lipodystrophy Market Drivers<\/p>\n<p style=\"text-align: justify;\">19 Lipodystrophy Market Barriers<\/p>\n<p style=\"text-align: justify;\">20 SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">21 Disclaimer<\/p>\n<p style=\"text-align: justify;\">22 DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">23 About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Epidemiology 2034<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;Lipodystrophy &#8211; Epidemiology Forecast to 2034&#8221; report delivers an in-depth understanding of the disease, historical and forecasted Lipodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Lipodystrophy Pipeline 2024<\/strong><\/p>\n<p style=\"text-align: justify;\">&#8220;Lipodystrophy Pipeline Insights, 2024&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Lipodystrophy market. A detailed picture of the Lipodystrophy pipeline landscape is provided, which includes the disease overview and Lipodystrophy treatment guidelines.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=lipodystrophy-market-expected-to-rise-2034-ionis-pharmaceuticals-regeneron-pharmaceuticals-boehringer-ingelheim-expected-to-drive-market\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lipodystrophy-market-expected-to-rise-2034-ionis-pharmaceuticals-regeneron-pharmaceuticals-boehringer-ingelheim-expected-to-drive-market\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lipodystrophy Market 2034 The Lipodystrophy market growth is driven by factors like increase in the prevalence of Lipodystrophy, investments in research and development, entry of emerging therapies during the study period 2020-2034. The Lipodystrophy market report also offers comprehensive insights &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/lipodystrophy-market-expected-to-rise-2034-ionis-pharmaceuticals-regeneron-pharmaceuticals-boehringer-ingelheim-expected-to-drive-market_730258.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-730258","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/730258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=730258"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/730258\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=730258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=730258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=730258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}